newsfilter
← Latest News
GlobeNewswire·

Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus

Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile ...